secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oncology Institute, Inc. (TOI)
CIK:        0001799191
Form:       8-K
Filed at:   2023-08-09T23:59:59+00:00
Accession:  0001799191-23-000029
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TOI Q2 revenue up 32% to $80M, net loss widens to $16.9M, reaffirms FY 2023 guidance
--------------------------------------------------------------------------------

- Revenue of $80M (+32% YoY); gross profit $15M (+36%); gross margin 18.8% vs 18.3%.
- Net loss of $16.9M vs $5.5M loss in prior year; EPS $(0.19) vs $(0.06).
- Adjusted EBITDA $(6.9)M, flat YoY; cash & investments $98M as of June 30, 2023.
- Acquired Southland Radiation Oncology Network; patient visits up 14%, oral drugs dispensed up 38% YoY.
- Reaffirmed full-year 2023 guidance; management cites strong topline growth and momentum.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1799191/000179919123000029/0001799191-23-000029-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1799191/000179919123000029/toi-20230808.htm
  HTML page:      https://secwatch.observer/filing/0001799191-23-000029

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer